J-Code
-
Ryoncil® Granted J-Code by CMS, Streamlining Reimbursement and Expanding Patient Access
Mesoblast Limited announced that the permanent J-Code J3402 for Ryoncil, its cell therapy for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients, became effective on October 1, 2025. Assigned by CMS, the code aims to streamline billing and reimbursement, potentially broadening patient access to this first FDA-approved mesenchymal stromal cell product. While seen as positive, commercial payer adoption is crucial for realizing Ryoncil’s full potential. Healthcare providers can now utilize J3402 for claims submitted for services rendered on or after October 1, 2025.
